{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:08:11Z","timestamp":1761901691780,"version":"build-2065373602"},"reference-count":7,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.msard.2020.102526","type":"journal-article","created":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T20:43:35Z","timestamp":1600548215000},"page":"102526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Anemia and sarcoidosis following treatment with alemtuzumab"],"prefix":"10.1016","volume":"46","author":[{"given":"Brandy","family":"Love","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9581-5090","authenticated-orcid":false,"given":"Jennifer A.","family":"McCombe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.102526_bib0001","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2020.102526_bib0002","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/WCO.0000000000000700","article-title":"Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm","volume":"32","author":"Cree","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2020.102526_bib0003","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1007\/s00415-018-8822-y","article-title":"Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: Practical recommendations","volume":"265","author":"Devonshire","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102526_bib0004","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1177\/1352458518771276","article-title":"Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment","volume":"24","author":"Graf","year":"2018","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2020.102526_bib0005","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2141.2007.06687.x","article-title":"The development of sarcoidosis with the use of alemtuzumab - clues to T -cell immune reconstitution","volume":"138","author":"Thachil","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.msard.2020.102526_bib0006","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1177\/1352458518790391","article-title":"Sarcoidosis following alemtuzumab treatment for multiple sclerosis","volume":"24","author":"Willis","year":"2018","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2020.102526_bib0007","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2141.2006.06324.x","article-title":"Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia","volume":"135","author":"Rezvany","year":"2006","journal-title":"Br. J. Haematol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820306003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820306003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:54:05Z","timestamp":1761900845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820306003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":7,"alternative-id":["S2211034820306003"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102526","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anemia and sarcoidosis following treatment with alemtuzumab","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102526","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102526"}}